Profile data is unavailable for this security.
About the company
Vimta Labs Limited is engaged in the business of contract research and testing organization. The Company is engaged in providing a range of services to biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, power, cement, oil and gas, ores and minerals, infrastructure and many other industries, government organizations as well as other industry participants. Its services include drug discovery, development, and drug life cycle management support services; preclinical research and testing services for medical device companies; contract research and testing for agrochemical and specialty chemical companies; and Food testing and analytical development services to support manufacturers, processors, farmers, and retailers; environmental regulatory services such as impact assessments and post project monitoring, to various industries, such as power and infrastructure, and EMI/EMC testing for electronic and electrical products/components.
- Revenue in INR (TTM)3.21bn
- Net income in INR534.03m
- Incorporated1990
- Employees1.43k
- LocationVimta Labs LtdPlot No.141/2 & 142IDA, Phase-II, CherlapallyHYDERABAD 500051IndiaIND
- Phone+91 4 027264141
- Fax+91 4 027263657
- Websitehttps://vimta.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race Oncology Ltd | 45.58m | -756.63m | 13.67bn | -- | -- | 13.62 | -- | 299.96 | -0.0839 | -0.0839 | 0.0051 | 0.1075 | 0.0355 | -- | 0.9201 | -- | -58.97 | -46.49 | -63.04 | -48.68 | -- | -- | -1,659.82 | -2,995.74 | -- | -- | 0.00 | -- | 40.68 | 116.86 | -39.26 | -- | -- | -- |
| TOT Biopharm International Co Ltd | 11.36bn | 104.61m | 14.67bn | 572.00 | 131.65 | 1.74 | 19.80 | 1.29 | 0.0133 | 0.0133 | 1.44 | 1.01 | 0.6899 | 2.44 | 6.40 | 1,899,506.00 | 0.6356 | -20.01 | 0.8392 | -25.21 | 72.02 | 74.74 | 0.9212 | -68.53 | 1.63 | 2.98 | 0.3465 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
| Jacobio Pharmaceuticals Group Co Ltd | 270.55m | -4.22bn | 14.72bn | 298.00 | -- | 1.40 | -- | 54.41 | -0.5014 | -0.5014 | 0.0321 | 1.23 | 0.016 | -- | 2.41 | 82,840.85 | -24.89 | -45.76 | -28.66 | -49.30 | 3.45 | -- | -1,560.88 | -372.22 | -- | -- | 0.1794 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
| Mabpharm Ltd | 1.77bn | -2.41bn | 14.77bn | 297.00 | -- | 10.99 | -- | 8.35 | -0.054 | -0.054 | 0.0395 | 0.03 | 0.164 | 0.1937 | 3.26 | 469,940.00 | -22.38 | -21.42 | -31.11 | -27.49 | 86.91 | -- | -136.47 | -486.40 | 0.6836 | -22.44 | 0.679 | -- | 55.87 | -- | 0.694 | -- | -26.85 | -- |
| Heartseed Inc | -54.30bn | -54.30bn | 15.70bn | 39.00 | -- | 4.69 | -- | -- | -- | -- | -- | 277.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 20.01 | -- | 0.0011 | -- | -30.93 | -- | -4.30 | -- | -- | -- |
| Pharma Foods International Co., Ltd. | 33.75bn | 1.74bn | 15.71bn | 642.00 | 8.77 | 2.41 | 7.03 | 0.4656 | 113.47 | 113.47 | 2,185.12 | 412.69 | 1.71 | 2.10 | 14.00 | 96,802,180.00 | 8.81 | 8.63 | 25.38 | 22.06 | 78.45 | 80.64 | 5.16 | 4.13 | 0.8875 | 81.16 | 0.5933 | 27.65 | -9.37 | 42.62 | 4.02 | 45.01 | 28.23 | -- |
| Vimta Labs Ltd | 3.21bn | 534.03m | 16.88bn | 1.43k | 32.02 | 4.92 | 19.43 | 5.26 | 23.73 | 22.23 | 142.67 | 154.59 | 0.7851 | 2.76 | 3.66 | 2,247,794.00 | 13.06 | 10.53 | 15.64 | 12.77 | 78.17 | 73.65 | 16.64 | 12.16 | 1.88 | 38.96 | 0.0328 | 5.58 | 0.0223 | 8.40 | -14.87 | 10.13 | 35.88 | 0.00 |
| Imugene Ltd | 0.00 | -8.20bn | 18.73bn | 0.00 | -- | 2.85 | -- | -- | -0.0211 | -0.0211 | 0.00 | 0.0162 | 0.00 | -- | -- | -- | -85.91 | -44.42 | -95.62 | -47.46 | -- | -- | -- | -- | -- | -- | 0.0053 | -- | -- | -- | -294.78 | -- | 136.28 | -- |
| Hua Medicine | 1.27bn | -3.07bn | 19.58bn | 172.00 | -- | -- | -- | 15.41 | -0.2889 | -0.2889 | 0.1195 | -0.0364 | 0.0779 | 1.51 | 3.31 | 661,951.30 | -18.84 | -25.61 | -23.63 | -28.81 | 37.72 | -- | -241.76 | -1,654.70 | 4.64 | -- | 1.14 | -- | 335.31 | -- | -3.80 | -- | 14.07 | -- |
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 30 Jun 2023 | 326.85k | 1.47% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 113.56k | 0.51% |
| American Century Investment Management, Inc.as of 03 Oct 2024 | 3.24k | 0.02% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 2.63k | 0.01% |
| DFA Australia Ltd.as of 30 Sep 2024 | 532.00 | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 30 Sep 2024 | 118.00 | 0.00% |
| Bandhan AMC Ltd.as of 30 Sep 2024 | 96.00 | 0.00% |
